Human Cardiac Drug Response Prediction
Human Cardiac Drug Response Prediction
FilamenTech helps cardiac drug developers turn preclinical assay, tissue, and animal data into mechanistic, human-relevant predictions of cardiac drug response using MUSICO, our physics-based simulation engine.
Level 1
Level 2
Level 3
MUSICO provided the mechanistic simulation framework published in PNAS 2024 with Bristol Myers Squibb co-authors, quantifying how mavacamten (CAMZYOS™) stabilizes myosin in the parked state while preserving cardiac reserve.
Reference to Bristol Myers Squibb reflects co-authorship on Ma, Prodanovic, Mijailovich et al., PNAS 121(8), 2024, and does not imply commercial endorsement of FilamenTech’s products or services.
Rank compounds, decouple mechanisms, predict human cardiac functional response.
Translate protein restoration into functional cardiac response hypotheses.
Add mechanistic human interpretation to cardiac assay and tissue-service packages.
Preclinical cardiac assays can show that a mechanism changes force, kinetics, calcium sensitivity, or tissue behavior. The hard question is whether those changes translate into human cardiac benefit or risk. MUSICO bridges that gap by connecting molecular mechanism to human-relevant cardiac function.
FilamenTech’s mechanistic simulations connect molecular dysfunction to cardiac performance, enabling mutation-specific insights into disease progression and therapeutic response.
We are excited to announce FilamenTech’s participation in a new scientific project called “Analysis Tools for Fiber Diffraction of Muscle” (R01GM144555), supported by National Institute of General Medical Sciences of the National Institutes of Health. Principal investigator is Thomas C. Irving from Illinois Institute of...
FilamenTech has recently started a collaboration with prof. Aleksandar G. Ostrogorsky from Illinois Institute of Technology, Chicago, IL, USA on performing simulations and data analysis for the optimization of the DiGS experiments conducted on Earth and at the ISS (International Space Station) within the project:...
Over the last 4 years, FilamenTech’s co-founders prof. Srboljub Mijailovich and Momcilo Prodanovic, along with FilamenTech’s scientific board members were involved in the project called “SilicoFCM – In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy” (No 777204),...
Assess whether your data supports a MUSICO prediction workflow.
Decision-grade mechanistic prediction for one program question.
Embed MUSICO insights into compound ranking and translational decision-making.
Human cardiac prediction from data you already have.
FilamenTech develops multiscale mechanistic simulation workflows that help drug-development teams translate assay, tissue, animal, mutation, and structural data into human-relevant cardiac and muscle predictions.
Boston • Belgrade
Start with a focused pilot.
Evaluate mutation effects, drug responses, or translational hypotheses using mechanistic simulation workflows tailored to your program.
© 2026 FilamenTech. All rights reserved.
Created by Starter studio.